Replay available

Neurocrine Biosciences (NASDAQ:NBIX) Q2 2022 Earnings Call

Neurocrine Biosciences (NASDAQ:NBIX) Q2 2022 earnings call, held 2022-08-04. Watch the replay and read the transcript on 6ix.

Thu, August 4, 2022 at 4:30 AMendedReplay
Neurocrine Biosciences (NASDAQ:NBIX) Q2 2022 Earnings Call
Company
Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Period
Q2 2022 earnings call
Date
Thu, Aug 4, 2022, 4:30 AM ET
Replay
Watch the replay on this page · 53 min
Results news release
Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance · Thu, Aug 4, 2022

On 6ix: 6ix.com/event/neurocrine-biosciences-inc-nbix-q2-2022-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:01 Good day everyone and welcome to today's Neurocrine Biosciences reports second quarter results. This time all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question and answer session. Please note today's call may be recorded and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Please go ahead.

0:35 Thank you, operator. Good afternoon, everyone, and welcome to our second quarter 2022 earnings call. With me are Kevin Gorman, our Chief Executive Officer, Matt Abernethy, our Chief Financial Officer, Eiry Roberts, our Chief Medical Officer, Eric Benevich, our Chief Commercial Officer, and Kyle Gano, our Chief Business Development and Strategy Officer. In our call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After our prepared remarks, we'll head into Q&A where we'll try to get to everyone's questions. And now I'll turn the call over to Kevin Gorman.

1:14 Thank you, Todd, and good afternoon. As Todd said, we're going to all keep our opening remarks short to give us enough time for your questions. Ingresa had a very good Q2, and coupled with our outperformance in Q1, we have had an excellent first half of the year. Eric is going to take you through the quarter in a bit more detail in just a moment. Now, in addition, I'm very pleased to say we continue to grow our pipeline, adding two new compounds with validated mechanisms of action in psychiatry, and Eiry will talk a bit about those two. Now, as you've seen in our press release, Our signal-seeking essential tremor study did not yield a strong enough data set to warrant any further development of this compound in ET at this time. While disappointing, we have a rich and diversified portfolio, and these resources will be rapidly redeployed.

2:05 Now, finally, I'd like to say that I'm very pleased with the overall performance of the company thus far this year. We, and here I mean the larger we, all of business and society, are dealing with the transition out of a pandemic and into an endemic Thank you for joining us. I'd like to turn it over to Matt now, please.

2:53 Good afternoon. The Andresa team delivered $350 million in sales during the second quarter, capitalizing on the strong new patient trends from Q1 and high levels of patient compliance. With the first half of 2022 now behind us, we are raising our annual aggressive sales guidance range to $1.35 to $1.4 billion based upon the trends we have seen so far this year. As you consider Q3, we expect third quarter sequential growth to be lower as a result of both the acceleration of COVID cases and the typical summer dynamics of pressure growth. On the financial front, during the quarter, we were able to retire 55% of our convertible debt to reduce potential dilution and maintain the financial flexibility we need with over $1 billion in cash.

3:46 Now, over to Eric.

3:49 Thanks, Matt. Our team continues to do a great job executing on our commercial initiatives. Q2 ingressive performance was driven primarily by continued strong persistence and compliance rates for continuing patients. coupled with a record level of new patient starts. As Matt said, given the results through the first half of the year, we've raised guidance to a range that incorporates a couple of scenarios that may play out in the second half of the year. First, as it relates to internal factors, our ongoing direct-to-consumer advertising campaign called TD Spotlight continues to encourage patients and caregivers to help seek treatment for their TDs. Thus far, we've been pleased with the response and we plan to continue the campaign through the balance of the year.

4:34 In addition, the newest members of our expanded field force have been trained and have been in the field now for about a quarter. As we've highlighted before, we anticipate the benefit of our expanded sales organization to be tangible in the latter part of the year. Regarding what we've seen from an external perspective, new COVID variants continue to provide headwinds for our customers, while telemedicine is still being utilized by psychiatrists with roughly half of their patients. Over the past five years of the Ingressa launch, we've seen a pattern of seasonal challenges in the third quarter, which has typically softened growth a bit relative to Q2. Therefore, given current dynamics, I would characterize the low end of the new guidance range to be more impacted by COVID, telehealth, and Q3 seasonal slowdown, and the higher end of the range to be less impacted by external factors, which we are working diligently to mitigate.

5:29 In closing, we're making steady progress improving the diagnosis and treatment rates for tardive dyskinesia in the U.S., This is still a mostly underdeveloped market, and we are well positioned to continue driving treatment rates higher to help even more TD patients than ever before. With that, I'll turn the call over to my colleague, Dr. Eiry Roberts.

5:49 Thank you, Eric, and good afternoon to everyone on the call. I'll start with a couple of updates from our late-stage clinical portfolio. We remain on track for the SNDA submission later this year of Balbenazine as a potential treatment for Huntington's disease. In addition, the Phase III adult and pediatric studies for Cronesophon as a potential treatment for congenital adrenal hyperplasia are progressing well, in line with our goal of delivering data in 2023. Moving to the earlier stage clinical portfolio, we were very pleased to announce the FDA's recent acceptance of the IND for NDI568, a selective orthosteric M4 agonist for the treatment of schizophrenia.

6:39 This is the lead molecule in our Muscarinic franchise collaboration with Sose Heptaris. and I want to take a moment to thank the teams both at Neurocrine and Sosaheptaris for their hard work in successfully progressing this molecule into the Phase 2 study, which will begin enrollment in the near future. Along with examining the opportunity to expand beyond schizophrenia with 568, Our teams continue to work on advancing other novel muscarinic agonists into the clinic, including a potential M1-M4 dual agonist. In addition to moving forward with NBI-568, this month we will initiate Phase 1 evaluation for a novel orally active small molecule, NBI-770, which targets a potentially important mechanism for the treatment of depression.

7:38 If we are successful in progressing to Phase II clinical development, we will divulge more about both the target and the molecule. But I can say that this mechanism of action has already been validated clinically by parenterally administered molecules. If successful, NBI 770 would provide the first oral treatment approach for this target in depression. Now I'd like to address the results of the signal-seeking study of NBI-104 in essential tremor. The team completed a high-quality, single-center study of NBI-104 in 30 patients with essential tremor. The intent of this study was to identify potential signals of efficacy and determine the tolerability of NBI-104 in this patient population.

8:28 NBI-104 was well tolerated at all doses studied, However, top-line efficacy results from the study were negative and failed to achieve statistical significance. The study produced a broad dataset beyond the top-line information, and the team is continuing to evaluate this data with the intent of presenting it at a future medical conference. Based on the totality of data from this study, at this time, we do not plan to proceed further with the clinical development of MBI-104 in essential tremor. It is important to note that these results do not impact the current Phase 2 study of MDI-104 in epilepsy with continuous spike in waves during sleep. Enrollment in this study is complete and we remain on track to disclose top-line results by year-end.

9:20 Finally, I'd like to congratulate our partners at the Mitsubishi Tanabe Pharma Corporation for all their efforts in getting valbenazine approved. We look forward to supporting their launch of DISCVAL for the treatment of tardive dyskinesia in Japan. With that, I'll hand things back to Kevin.

9:39 Thank you very much, Eiry, and operator, now we are ready to take questions. Reminder, at this time, if you would like to ask a question, please press the star and 1 on your touchtone sound. You can withdraw your question at any time by pressing the pound key. And we'll move first to Phil Nadeau with Cowan & Company. Please go ahead.

10:06 Good afternoon. Thanks for taking our questions and congratulations on a strong quarter. Just two for us. First, on the Q1 results for Ingereza, they're particularly impressive because are particularly impressive because Q1 wasn't as impacted by seasonal factors as other Q1s in the past. So I guess we're curious whether we can go into more detail as to what led to the increasing new patient starts in Q2. Was that strictly DTC? Were there any of those seasonal factors that did improve in Q2, maybe more than you had initially anticipated? And were there any one-time factors? It does strike us at the bottom end of your guidance, your renewed guidance, to just down cores in Q3 and Q4 versus the Q2 run rate.

10:54 So aside from COVID, we're curious how that could happen. And then the second question is on ET. We're just curious whether the data put into question in your minds the T-type calcium channel blockers, Generally, do you think that this was an issue with the disease, with the mechanism, or simply compound-specific? Thanks.

11:16 So, Phil, this is Matt. We're going to handle your first set of questions on the ingressive front, and then we'll handle ET as we get further into questions because we're going to try to stick to one question. You know, you're right. Q2 was an incredibly great quarter reflecting great mutation additions and then also surprisingly very high compliance rates. So, I'd say the beat was both internal and then obviously external. came from a nice step up in compliance and then also a continued trajectory of mutation additions that was fairly strong throughout the quarter. We wouldn't flag any one-time items, such as inventory or bulk purchases by any pharmacy. So it was a very clean, straightforward quarter. If you take a step back and think about our guidance range today, You know, it really reflects an over or around $300 million growth here.

12:16 And that's a pretty incredible feat coming out of COVID and then still dealing with the environment that we're dealing with right now. And as Eric mentioned in his prepared remarks, really the downside is very specific to COVID. I think we all see it popping up regionally. And that could cause some disruption at the bottom end of the range. and then at the top end of the range, it's all about aggregation on the Salesforce expansion side. So hopefully that addresses your question, Bill. Thanks. And I think our next question is from Brian Abrams with RBC Capital Market. Please go ahead.

12:57 Thanks. This is Alina for Brian. I just want to go back to 104. You know, I guess You know, can you just talk a little bit about, you know, why do you think that, you know, it might still be active in some of the epilepsies? And I guess the decision to continue is that, you know, institutions have to be across all the endpoints or, you know, is there any single that you might be able to tease out as you continue to look at the data or just a more bigger picture if you want on the therapeutic window? And then I guess, you know, as we go back to the epilepsies, are there, you know, any epilepsies where, you know, you might, continue thinking about bringing this drug in as well.

13:37 Yeah, so a couple of questions in there. On the first question, I think the patient populations, if you look between essential tremor and the epilepsy population that we're studying within CSWS, those are very different populations. And so I don't think you can infer directly from one population to the other. Also, to answer the question I think that Phil asked as well around what do we believe about this in the context of T-Tec calcine channel antagonists in essential tremor, It's really hard for us to comment on the other molecules in development, but what I can say about the trial that we ran was that it was a high-quality, single-center trial, well-controlled, and that as we looked at the data, the trial design and the way in which the trial played out actually were not responsible for the negative results. It was not a failed trial.

14:28 It was a negative trial. We saw some evidence of activity, but the signal was not sufficiently robust to hit statistical significance or to hit clinical relevance, either on the accelerometer or on the Tetris endpoints that we looked at. And in particular, the other thing I will say is that we had central assessments as well as local assessments on the Tetris, and there was high concordance between the two sets of assessments. So it was a robust data set. We'll continue to evaluate the data in more depth, but at this point in time, I think we are clear that we will not be moving forward with a central firm for 104. And we'll take our next question from Paul Matisse with Stifle.

15:14 Please go ahead.

15:17 Hey, thanks so much for taking my questions and congrats on the quarter. Over the past few years, you've been super conservative with just the upfronts that you've offered in business development. I think you've also been clear that your pipeline is high risk and CNS is difficult. But I guess given the failure of the EC program, given that there have been a number of setbacks, I'm wondering now, given your position of strength with Engraza, if there's any consideration that you could incorporate a bigger transaction if you have the capacity to do so, and maybe just give us a little bit of an update in your thinking there and whether we could see something more meaningful over this year or next. Thanks.

15:56 Thanks, Paul. I'm going to put that question to Kyle.

16:01 We've talked about this in the past. I think, you know, firstly on the outset, for business development versus internally discovered assets, we view them similarly in terms of probability of success. I think that's fair for all organizations to view it from that perspective. And when thinking about things that are strategic versus in licensing, I'd also add that we're really agnostic to structure and the scope of opportunities that we're looking at today. I think... The issues are that in the CNS space, we see the assets that are available bifurcated in either extreme in terms of being a late-stage commercial, higher value, higher expense items, and those that are higher science that are in earlier-stage development.

16:47 And I think we continue to evaluate those to see where their place would be in our own pipeline. So in a nutshell, those strategic types of deals are possible, and we look at those. This is as much as we see on the licensing front. In close, if you look at the pipeline today, you see about a dozen assets amid the late-stage development, a balance there with the new programs that we brought in from Phase 1 to Phase 3, and a balance of targets that are validated and those that are novel. And those are the types of things that we look at when we create the pipeline and manage to sustain it over time. Thank you for your questions.

17:59 Are you saying that compliance improved after that time, which is about, I don't know, what, five weeks into the quarter? And why would compliance meaningfully change? And I know you've talked about COVID, et cetera, but, you know, frankly, we've already had several COVID surges throughout 2Q, and that didn't seem to impact you on a great quarter. So I'm just trying to understand, you know, what part of this – Thank you.

18:38 Yeah, Suzanne, just to be clear on the compliance front, I wouldn't call it a huge surge of better compliance. It's something that you can only really take a look at over longer periods of time, so it's not something you have clear sight on, you know, a couple weeks into the quarter or five weeks into the quarter. We typically look at it on a quarterly basis to really get an understanding on what refill rates per patient looks like, and sometimes Slight changes in refill rates for patients definitely drives large revenue contributions. The good thing is patients are staying on medicine, and that's something that we've seen ever since the beginning of launch, and I think that's a testament to the medicine itself and our clinicians.

19:25 I would say in respect to COVID, we don't want this to be a COVID-centric call. We do see sporadic instances of COVID that are taking reps, doctors, patients out of the office. It just has caused some level of disruption. Our view is to always shoot as high as we can within every quarter, but on calls, give a really balanced view as to what the potential scenarios could look like. But Eric, do you have anything to add here?

19:59 Yeah, maybe just to chime in a little bit, you may recall, Suzanne, that on the Q1 call that we said we flagged that as a quarter that had a record number of new patient starts. And then now in Q2, we set another record. And I think that the new patient starts are a huge contributor towards the results in Q2. But, you know, we carried a lot of momentum coming out of Q1 into Q2, and those new patients that started in Q1, of course, as Matt said, you know, we saw really good persistence and adherence in Q2. And, of course, you know, when you have small changes in those measures of compliance, that can really add up when you've got a patient base as large as ours is now.

20:50 I would just flag the new patient starts as an important contributor. And with regards to Q3 and sort of the balance of the year, we have said that Q3 historically has been a slower growth quarter for various reasons over the five years of the launch. And so we want to make sure that investors understand that this year we don't expect to be any different than in years past. The COVID factor, is relatively newer compared to the early phase of the launch. But in general, Q3 has been a slower growth quarter, whereas Q2 has almost always been a really strong growth quarter for us. And moving next to Nina Petritogar with Citi.

21:40 Please go ahead.

21:43 Hey, guys. Thanks for taking my question. Congrats on the quarter. I was just wondering if you could talk a little bit about How much of an impact do you think the new sales reps had on the 2-2 number and how we should think about the impact there moving forward? I know, Matt, you did talk a little bit about that earlier, but it just seems like at the lower end of the guidance range, you're essentially assuming kind of no growth the next few quarters, and at the high end, you're assuming essentially similar level of growth from a dollar perspective to second half of last year. So just trying to understand how the new Salesforce factors in. Thanks.

22:22 Yeah, so let me just take a step back and say that, you know, we've raised our guidance. And what is now the bottom end of our range was the top end of the range at the time that we issued guidance at the beginning of the year. And so, you know, we feel very good about the trajectory that we've been on thus far in 2022. and we're not expecting the second half of the year to be a no growth scenario. But we do have a range and we wanted to make sure everyone understands where we expect to end up by the end of the year. So that being said, with regards to the first part of your question, which was about the sales force, you know, what we've guided externally is that it's going to take a bit of time for all these new people to hit their stride. Everyone's working really hard to get integrated into their territories, to meet their customers, et cetera. But it takes a little bit of time for folks to, you know, to really get up to speed. We've hired very experienced people in LTC and in neurology and the backfields in our site team.

23:34 But just because they're experienced doesn't mean that they've got experience in TD and with Ingresa. So I think we're doing all the right things to set everyone up for success, and we're doing a really great job in terms of teamwork and collaboration, handing off customer relationships, sharing best practices, etc., But in terms of when we start to see a more tangible impact from the expanded field sales team, it's our belief based on our prior experience with field expansion that it would be towards the latter part of the year. So in summary, we're doing all the right things. We think they are making a contribution, but it's early yet to gauge the degree of that. And we'll take our next question from Jay Olson with Oppenheimer.

24:25 Please go ahead.

24:26 Oh, hey, congrats on the quarter, and thank you for taking the question. Can you talk about how your 5, 6, 8 selective M4 agonists will be clinically differentiated from other muscarinic programs like Karuna and Seravel, and what sort of read-across Thank you, Jay.

24:54 We're very excited about our 568 program, and we're really pleased to be able to rapidly get to a point with the FDA that they cleared us to start the Phase 2 study, which will be beginning enrollment very soon. This is a Phase 2 dose-finding study in patients with schizophrenia. and I think just to remind you 568 is an orthopheric agonist, selective agonist of M4 and so it is the first molecule of that nature to go into this disease area. I think we were very are encouraged by the validation of the M4 mechanism by both Karuna and Cerevel in acute psychosis, but clearly the profile of a direct agonist versus a positive allosteric modulator versus a non-selective muscarinic agonist It's difficult to predict right now the differentiation between those molecules. For us, the most important thing is for us to get going with our Phase 2 study.

25:54 We believe it's a well-designed dose-finding study that will allow us to answer some key questions in this disease area, and that we'll be progressing as rapidly as possible to enroll that study.

26:05 Great. Super helpful. Thank you very much. And we'll move back to Carter Gould with Barclays. Please go ahead.

26:18 Great, guys. Thanks for taking the question. I wanted to come to the DTC campaign. It's went now over a year. And I wanted to kind of suss out how you think that's contributing, the magnitude there, and if there's been any thought to Expanding that or how you see that kind of evolving going forward. Thank you.

26:44 Yeah, we're really pleased with the DCC campaign and meeting our expectations in terms of the behaviors that we're looking for in the target patient and care partner population. You know, we've consistently seen high rates of people visiting the website, lots of downloads and page views. and, of course, people registering to receive information from the company. Ultimately, it's an important contributor towards new patient starts. And we continue to look at key performance indicators and assess the return on investment of the DTC campaign. And as I mentioned in my prepared remarks, we're pleased with it and we're going to continue through at least the end of the year.

27:33 will reevaluate when we get a little further down the road what the plan looks like for 2023. In terms of how much of a contributor it is to our success, you know, obviously we've got a lot of different initiatives at any given time, but we think it's an important contributor along with other marketing programs with the expanded field for us, etc., and all of these things together are what's really driving the strong growth that we've seen this year, the raising of our guidance and our expectation that, you know, we've got a lot of headroom here in terms of this market opportunity and we're going to continue to invest as we see appropriate. Question from No Park Robber with J.P. Morgan.

28:23 Please go ahead.

28:26 Hey, guys. Thanks for taking the question, and congrats on the quarter. Matt, I'm sorry if I missed this in your opening comments, but maybe you could highlight a little bit about the R&D expense increase for the year and what's really driving that and which programs specifically. Thanks so much.

28:45 Yeah, hi, Anupam, nice to hear from you. On the R&D expense, that is $30 million, and it's a milestone associated with the Sociate Aparis Muscarinic Program. So we triggered that milestone with the acceptance of the R&D and initiation of the Phase II. So it's purely a milestone-related expense. And we'll move next to Brian Scorney with Baird. Please go ahead.

29:18 Hey, good afternoon, everyone. Thanks for taking the question. So I was hoping to get any thoughts on the SMDA content in Korea. I know it's about a year before you would launch, given the timeline. I just wondered if you started doing any work to understand how this might accelerate

29:34 growth. Do you think this will be a switching market from D-tetrabenazine? Will this be targeting DMAT-naive patients? I was trying to think ahead based on What are the current needs in this market, where you would anticipate drawing patients from, and how much of an inflection that can drive?

29:52 All right, well, yeah, we're certainly excited about the opportunity. We're very excited about the data. Obviously, we have to see what the labeling looks like, but we're pretty far along in our planning. One way to think about this is that this is completely incremental to our TD market. You know, there's very, very little Off-label prescribing of Ingresa. And so, we think that Ingresa offers a differentiated treatment option for patients with Huntington's disease that are suffering from clear form movements. As you may know, the majority of patients that have Huntington's chorea are not treated with DMAT2 inhibitors for various reasons. And so the majority of our growth opportunity is really to tap into that untreated Korea patient population. You know, certainly there will be some patients that are treated with current treatments that may choose to switch to Ingreza, but we don't view this as primarily a switching market opportunity. Our aim is to really address the majority of patients that aren't being treated for various reasons. And we think that the profile that we have in TD lends itself well in terms of those product attributes that make us the most preferred product in TD hopefully will translate well into the HD market.

31:25 So we're looking forward to that opportunity next year. And we'll move next to Chris Shibutani with Goldman Sachs. Please go ahead. Thank you very much. Congratulations on a very strong quarter. I wanted to ask Kevin in particular your point of view on a bigger picture topic that's come across this week, especially to the commercial pharmaceutical companies, and that is of the potential for legislation that would involve potential for Medicare drug pricing negotiations. Discussions from different companies talk about the implications on certain types of drugs, small molecule versus biologics, exposures to different payer groups, impact on how people are thinking about investing in innovation, pipeline strategy. Could you share your thoughts from your vantage point and also remind us what any implications you feel might be for Merocrine specifically?

32:28 You know, Chris, it's a very timely and important question, maybe a little too timely. There's a lot of moving parts that are taking place right now. You read the press reports as early as this morning, as well as our own Washington, D.C. team suggests things still appear to be very much in flux. As such, it would be premature for me to talk about that or speculate on the impact on our company. or whatever ultimately ends up in the bill. But when there is clarity, we will be talking about this and we will be giving specific thoughts on that. I'm sorry that I don't want to speculate now. I think the term is the sausage still appears to be made.

33:19 And so we'll wait and see how that turns out. We'll take our next question from Miles Venture with William Blair. Please go ahead. Hey, congrats on the quarter. Just on 5-6-8, are you planning alongside the Phase 2 study to run a separate study monitoring cardiovascular effects of that mechanism? And maybe within the Phase 2 study, do you plan to do an adjunctive therapy? Thanks.

33:53 We don't have plans for adjunctive therapy in the current study. The current phase two study is focused on understanding dose responsiveness in acute psychosis. We will have extensive safety measures throughout the study, including cardiovascular assessments. But at this time, we are not planning a separate cardiovascular study. We really intend to see what the information looks like from the current, the ongoing phase two study and then decide how to proceed from there, given that obviously this is a selective M4 agonist rather than the molecules that have been in the clinic before. And we'll move next to Danielle Brill with Raymond James.

34:38 Please go ahead.

34:40 Hi, guys. Good afternoon. Thanks so much for the question. I just have a quick follow-up about the contribution of the new stale tires. And I guess maybe I'll ask a little differently, but has the prescribing mix shifted at all, or is it still 80% contribution from psychiatrists, 20% neurologists?

35:04 Yeah, so, you know, we're still seeing in general that the mix of prescribers is pretty similar to what it was a quarter ago. Like I said, they've been very recently deployed. And we are seeing positive signs in terms of both the activity and the response to the promotional efforts. But I would caution everyone from attributing the strong Q2 to the fact that we, you know, deployed an expanded field sales team. Those were essentially simultaneous events. But, you know, ultimately, you know, we do expect that with the expansion of the field sales team and the deployment into three distinct segments, that we're going to be able to go deeper in psychiatry, neurology, and, of course, LTC is essentially an untapped market for us previously. And so we'll be able to provide, I think, more detail when we get further along in the year in terms of how things are shaping up.

36:09 But we're very optimistic about the opportunity that we have with this larger field organization to be able to support and reach more customers. And we'll take our next question from Laura Chico with Wedbush.

36:28 Please go ahead. Good afternoon, and thank you for taking the question. I guess, you know, back to Ingresa, how do you think that we're actually about the peak run rate at this point? And I guess I'm just trying to understand how the outlook may have changed in recent quarters following not only the adjustments to the field force, but also in terms of how you might be thinking now about the exclusivity runway for Ingresa. Thank you very much.

36:56 Hi, Laura. This is Matt. On the exclusivity front, we feel very confident with the strength of our patent estate that we'll have protection into the mid-2030s, and we feel very good about that. As it relates to the peak, we've not given any commentary associated with what we think the peak will be. But I think the growth that you've seen so far this year just really reflects how much of an opportunity we still have in the tardive dyskinesia market. We think there's only 25% of patients that have received a diagnosis and only half of those being treated at this point. We look at this market as continuing to be untapped, and the growth is even reflective of an environment where telehealth is still 50%. So, Eric, anything to add there?

37:50 The only other things that I would point out is that in addition to the majority of patients still being as yet undiagnosed, about half the time when patients are diagnosed with TD, they're not offered a VMAT2 inhibitor. And so there's a significant amount of progress still to be made in terms of making sure that people with TD get diagnosed and they get offered effective treatments. The other thing I would point out, and it somewhat relates to the last question as well, is that we've seen tremendous growth in the number of advanced practice providers that are now diagnosing and treating TD. They're an important part of the care system, both in neurology and in psychiatry.

38:38 We're talking about nurse practitioners and physician assistants here. With the expansion of our field organization, we're going to be able to reach and educate more of those important healthcare providers. And so even though we're five years into launch, we feel like there's a long way to go in terms of continuing to develop the TD market and to help as many patients as possible. And we'll take our next question from Charles Duncan with Cantor Fitzgerald.

39:12 Hey, it's Avi on the line for Charles. Thank you for taking our question.

39:16 So we were wondering if this past quarter's performance was primarily driven by new prescribers or, I guess, an acceleration in the growth of prescriber base or if it was more from greater depth among current prescribers. Thank you.

39:37 Yeah, what we've long said is a lot of the opportunity that we have left with the ingress and the development of the chart of this major market is really going deeper with existing clinicians. We did see new writers this quarter, and we are starting to call on a new segment in LTC as well as with more focus in neurology. So over time, we would expect that we will have a nice increase in the prescriber base. But I'd say by and large, the biggest majority of our scripts came from existing prescribers going deeper.

40:15 Yeah, just to tack on to that, it's not so much about the new writers. It's about the new patient starts. And as Matt said, not just increasing the breadth, but the depth. of our business is important. We'll continue to see new prescribers get added over time, especially as we tackle new market segments like LGC. But You know, ultimately, most of the patients that have TB are within the practices that we're already calling on. And we continue to focus on helping people recognize TB to make the appropriate distinction between TB and other drug-induced movement disorders. And, of course, to offer effective treatment with Ingreza when it's diagnosed.

41:06 Next to Evan Seegerman with BMO Capital Markets. Please go ahead.

41:13 Hey, guys. Keith Thon here for Evan. Thanks for taking our question.

41:17 Just wondering if you could provide any color on the Ingress inventory build, and then to that end, does the DTC program impact channel dynamics or revenue recognition cadence? Thank you. Yeah, so on the inventory front, we've been at a very stable inventory position, so nothing to flag there. And I believe I commented on that earlier. So the results were fairly clean this quarter. And as Eric mentioned on the direct-to-consumer advertising campaign, all the indicators are pointing towards a very successful trend. and all the website metrics and call center metrics. And so I would say it's performing at our expectation.

42:10 The only other thing I would add, Keith, is that in terms of does DTC impact channel dynamics? No, it doesn't. Ultimately, you know, we have a and a limited pharmacy network. It's a large limited pharmacy network and we think that it meets the needs of our customers from an access and flexibility perspective. But any prescriptions that are written for Angreza are going to get filled through that channel. Next to Mark Goodman with SVP. Go ahead.

42:50 Yes, hi. I turned a little late, so I'm not sure if you actually answered this question about gross to net and average selling price in the quarter, if you can answer that. But more importantly, I was curious, I know you're probably finishing up on the payer contracting for next year, if you can give us a sense of how you're thinking about ASPs into next year as well for Ingressa. Thank you.

43:15 Yeah, so for the quarter, we saw a rebound in net revenue per script as we had expected, a bit above $5,400 and would still lead everybody to a guide for this year of $5,400 net revenue per script. It's a bit premature for us to cover 2023 in terms of both coverage as well as net revenue per script, but it's something that we will obviously give some insight to as the year progresses. And, you know, if we did see, Mark, at this time, something structurally that was going to change that would give us a lot of concern over our ability to continue to allow patients to have access to this medicine or a significant impact to our price when we're thinking about 2023, we would give everybody as much of a heads up as possible. And sitting here today, that's not our expectation.

44:14 This is next to David Anselum with Piper Sandler. Please go ahead.

44:22 Thanks. Sorry if you addressed this, but on ingressa, can you just go through the extent to which you're getting contribution from the long-term care setting? I know this is an opportunity you talked about in the past. And maybe looking ahead, What's your view on how big of a portion of the mix that could be over time? Thank you.

44:53 Yeah, so our long-term care team has been very recently deployed into that setting. And so it's very early in the process yet in terms of being able to – you know, generate that business. We certainly feel very confident about the opportunity, otherwise we wouldn't have, you know, built a dedicated sales force there. You know, we recognize that in nursing homes, in other types of residential facilities that care for patients, that there is a significant use of antipsychotics and other medicines that can cause TD.

45:38 This is a care segment that we were very interested in and attracted to at the time that we were planning the launch. But unfortunately, you know, we didn't feel like we were in a position to introduce and grow into this care segment during the initial launch phase, really because of capacity constraint issues. And so we prioritized focusing our go-to-market approach on outpatient neurology, with an emphasis on movement disorders, as well as private practice psychiatry and community mental health clinics. And that's really represented the focus for the first few years of the launch. And then when we got into last year, we revisited our readiness to take on long-term care. We made the decision to reorganize and expand our field sales team. We felt the time was right to tackle this.

46:38 From a scale perspective, it's probably not as large of an opportunity as the other segments that I've described, but it's meaningful and it's significant. And there's a large number of patients that could benefit from Engreza, which is the most important thing. So as we get further down the road, I'll be able to provide more color in terms of how things are shaping up, not just with the long-term care team, but also our new dedicated team. and expanded focus in neurology with our neurology sales force. So stay tuned. Move next to Amin Fathia with Miram and Company. Please go ahead.

47:24 Thank you for taking the question. This is Amin for Amin. I was wondering if you can give some color on Obviously, you created a dedicated Salesforce for the neurology side of Ingereza's business. What are the early feedbacks that you are seeing there, and how should we think about the impact of this expansion of the Salesforce for the remainder of the year?

47:58 Yeah, with regards to neurology in particular, the feedback's been very positive. You know, we've said that neurology has represented about 15 to 20% of our business for Ingresa. Certainly, we think that it could be more. And we, you know, we, did the analytics support the case for expanding our focus in neurology with a dedicated sales team? And really, we've got a team that has two products with Ingresa and Angensis that they can bring into neurology. And we think that, frankly, they work well together, meaning, for example, that Angensis can really help the neurology team get access to some of these movement specialists.

48:45 And so we're very pleased with the early feedback. About three-quarters of the team we hired from outside the company, so they're still learning the ropes, so to speak, but they're quick learners. and we've started calling on a broader set of neurologists than what we were calling on previously with our smaller sales organization. So ultimately, we feel good about the investment. All the early signs are very positive. and as I said before, we think that there's a lot of growth opportunity in neurology that we couldn't really tap into under the old structure. So, as we get later in the year and into next year, I'll be able to provide a lot more color in terms of how things are going really across all three of those pair segments.

49:37 And we'll move next to Yatin Taneja with Grugenhall Partners. Please go ahead.

49:45 I have a question on 352. Could you talk about the expectation from the adult focal onset seizure study that you are running? I understand it is a dose-finding study, but in terms of the product attributes, in terms of the signal from efficacy standpoint, what would you like to see for you that would warrant further development in a bigger study? Thank you.

50:13 Thank you. Yeah, we're very excited about the 352 program, both in focal onset epilepsy and in the rare disease epilepsy, STNA, and we have those two Phase II programs going on in parallel. For the focal onset seizures, that is a dose-finding study. In adults, we are evaluating as the primary endpoint there the seizure frequency using a diary approach. And so that will be the primary endpoint at the end of the study. We also obviously will be looking at tolerability, the adverse event profile, and the exposure to the drug in that setting, in addition to the quality of life and other measures. that are described, I think, in our posting around this study. Obviously, we'll be looking at the totality of the data from this Phase 2 dose-finding study in order to understand whether or not to progress.

51:09 But to date, based on the Phase 1 data from this program, we've been very encouraged by the profile of the molecule, and we intend to read up the data from this study sometime next year. And it looks like we got to the end of all the questions. I would now like to turn things back to Kevin.

51:31 Thank you very much, Chloe, and thank you everyone today, especially for the focus of your questions. It allowed us to get through everyone, and I hope you found our answers to be transparent and to be helpful. We've had an extremely good first half of the year, and I'm really looking forward to continued growth in the second half of the year. We've made significant investments in Ingressa, over the last six to 12 months, and we expect those to increase our reach to our patient population as the year progresses. I'm also very optimistic about our pipeline that we've built to date. Over the next 18 months, we have a number of important clinical readouts. To remind you, we have five pivotal programs. We have seven phase two programs, and we're adding a new and very interesting phase one program that will be talking about all of those more in the coming months.

52:26 So overall, I think in what is still a challenging environment, NURCAN has done an outstanding job here, and we are looking forward to getting together with many, if not all of you, throughout the remainder of the year. So once again, thank you very much for your attention. This does conclude today's program. Thank you for your participation. You may disconnect at any time. Have a wonderful evening.

Follow Neurocrine Biosciences, Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Todd Davis

Vice President, Investor Relations

Kevin Gorman

Chief Executive Officer

Matt Abernethy

Chief Financial Officer

Eric Benevich

Chief Commercial Officer

Eiry Roberts

Chief Medical Officer

Phil Nadeau

Analyst, Cowen & Company

Brian Abrams

Analyst, RBC Capital Markets

Paul Matise

Analyst, Stifel

Nina Petritogar

Analyst, Citi

Jay Olson

Analyst, Oppenheimer

Carter Gould

Analyst, Barclays

Danielle Brill

Analyst, Raymond James

Laura Chico

Analyst, Wedbush

David Anselum

Analyst, Piper Sandler

Amin Fathia

Analyst, Miram and Company

Yatin Taneja

Analyst, Guggenheim Partners

More from Neurocrine Biosciences, Inc.